bnnbloomberg.ca
Pfizer’s Tight Paxlovid Rein Stymies Drug Combination Research - BNN Bloomberg
Pfizer Inc. is resisting requests for study supplies of its Covid-19 pill, Paxlovid, disappointing researchers who say combining the $22 billion therapy with other drugs might stave off resistance.